DEVON ZAFUTO: Open Payments
NPI 1497497150 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 62 payments from 15 companies in 2025. Trend: 2023 $1,245 · 2024 $2,255 · 2025 $1,352
Food & beverage: $1,352
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $386 |
| ABBVIE INC. | 14 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $152 |
| Vanda Pharmaceuticals Inc. | 10 | $135 |
| Lundbeck LLC | 5 | $113 |
| Bausch Health US, LLC | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Neurocrine BioSciences, Inc. | 2 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
Products named: VIVITROL, VRAYLAR, CAPLYTA, REXULTI, HETLIOZ, ARISTADA, INGREZZA, APLENZIN.
Industry payments across NC — which companies pay providers there.
